about
Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesLooking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.Overview of metabolite safety testing from an industry perspective.Novel MS solutions inspired by MIST.Early human ADME using microdoses and microtracers: bioanalytical considerations.From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.The early estimation of circulating drug metabolites in humans.Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications.The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods.Preparation of labeled human drug metabolites and drug-drug interaction-probes with fungal peroxygenases.Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.A convenient chemical-microbial method for developing fluorinated pharmaceuticals.Are multimetabolite methods fit-for-purpose for supporting toxicology studies?Bioanalysis: the best of 2009.Exploring PTDH-P450BM3 Variants for the Synthesis of Drug Metabolites.Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
P2860
Q27689400-67535AFA-CE04-4849-AA14-5540D08479ACQ30662550-0F51EDAC-9934-4313-A1B8-22876603F84EQ34657381-E1669F11-D4F7-4BCB-8F2F-CBCB1B4F31C2Q37810226-D07C98E4-2CBF-474B-8A9F-49A4DD3BE7A8Q37810227-395D58ED-AFCC-403A-B782-A1045559AACBQ37810230-99721B32-A40F-4B38-B362-F62E7EBF606CQ37810234-7AC8FC9E-D848-480C-806F-08D5CC33BD51Q37859007-64912ADE-3F4C-4783-9FA7-78D73F81E2B1Q38017286-C5CC8CF8-3084-442A-91FD-7FBDFF8E296BQ38120833-D9E4E4D3-22DE-4859-902D-B6B08A7E39F4Q38769600-B2CF8CD8-8B94-4794-B317-4F33BD07C44CQ39067502-45BFAF73-540D-4E8F-916B-F62B3A30C200Q39305815-E9A44775-371F-427E-8B9F-813CE50EC5F3Q41035651-C2568EDD-BFA0-467F-BE6F-B6F8D298317EQ45287118-B8582A62-5B93-4DEB-A4B1-6AD821ECAA62Q46155760-6DE37157-4A6B-4A3A-916A-3F7E33882C35Q48303993-EE0B8394-3191-42CD-B2A7-2BE945FFC0F5Q49579327-08693D88-9E79-4349-88C4-88C2CAD68D46Q53163947-45FCEDAC-2EB7-450A-AE7D-1472E1264B7D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolites in safety testing.
@en
Metabolites in safety testing.
@nl
type
label
Metabolites in safety testing.
@en
Metabolites in safety testing.
@nl
prefLabel
Metabolites in safety testing.
@en
Metabolites in safety testing.
@nl
P2860
P356
P1433
P1476
Metabolites in safety testing.
@en
P2093
Abigail Jacobs
Timothy W Robison
P2860
P304
P356
10.4155/BIO.09.98
P577
2009-10-01T00:00:00Z